GleamWall
中文EN

RLMD RELMADA THERAPEUTICS, INC.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1553643 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-16.9%
TTM EPS YoY59.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-64.7%
ROA-59.7%
ROIC (approx.)-54.7%
Asset turnover—

Leverage & solvency

Liabilities / assets5.6%
Debt / equity0.00x
Current ratio26.37x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.79x
Accruals ratio-12.6%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue————————
R&D expense$9.22M$8.39M$8.09M$8.07M$4.04M$2.82M$11.95M$11.00M
SG&A expense$3.88M$6.62M$11.37M$12.26M$6.29M$7.40M$6.27M$8.08M
Operating income-$13.10M-$15.01M-$19.46M-$20.33M-$10.33M-$10.22M-$18.22M-$19.08M
Net income-$13.86M-$12.91M-$19.05M-$19.87M-$10.09M-$9.87M-$17.56M-$18.66M
EPS (basic)-0.12-0.11-0.22—-0.30-0.30-0.58—
EPS (diluted)-0.12-0.11-0.22—-0.30-0.30-0.58—
Weighted avg. shares (diluted)112.44M112.38M86.60M—33.19M33.19M30.41M—
Balance sheet
Cash & equivalents$5.72M$11.33M$9.78M$3.50M$1.38M$1.35M$1.15M$3.86M
Short-term investments$196.40M$206.40M$224.19M$89.51M$12.50M$19.27M$25.91M$41.05M
Current assets$205.05M$219.04M$235.34M$93.98M$14.85M$21.09M$27.66M$45.80M
Total assets$205.30M$219.06M$235.36M$94.00M$14.88M$21.12M$27.68M$45.82M
Current liabilities$7.78M$7.42M$12.89M$6.43M$5.19M$5.13M$5.23M$10.29M
Total liabilities$11.56M$12.50M$16.63M$7.49M$5.41M$5.17M$5.24M$10.30M
Shareholders' equity$193.74M$206.56M$218.73M$86.51M$9.47M$15.95M$22.44M$35.52M
Shares outstanding106.69M106.67M104.89M73.33M33.19M33.19M33.19M30.17M
Cash flow statement
Operating cash flow-$12.59M-$9.61M-$15.07M-$14.60M-$6.72M-$6.40M-$18.07M-$8.80M
Investing cash flow$6.95M$17.59M-$135.23M-$76.93M$6.75M$6.68M$15.36M$11.35M
Financing cash flow$17,750-$6.42M$156.57M$93.64M$0——-$172,487
Stock-based compensation$1.02M$902,900$956,186$3.28M$3.61M$3.45M$3.57M$6.73M
Share buybacks$0$6.46M$3.36M—————

Free plan shows the latest 8 periods; Pro shows all 63 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.